Grünenthal is a global leader in pain management. Our purpose is to change lives for the better – and innovation is our passion. We are driven to seek effective, life-changing medicines and solutions for patients with severe diseases and high unmet medical needs.

... Company

A world free of pain. This is our shared vision. To bring it to life, we execute our strategy and work on our company’s culture – everyday, everywhere, every one of us.

... We are Grünenthal

Although firmly rooted in Germany, today we are very much a growing global Business.

... History

A mix of strong entrepreneurial spirit, close collaboration and outstanding performance define our approach to leadership alongside a commitment to diversity and inclusivity.

... Leadership

The Supervisory Board advises and controls the Corporate Executive Board and is elected by the shareholders’ summit.

... Supervisory Board

In view of our vision of a World Free of Pain, Grünenthal strives to provide effective medication to patients worldwide. Therefore, we continuously grow and expand our market presence and product portfolio, and we collaborate with commercial partners and multiple stakeholders from the pain management field and beyond.

... Global presence & sites

Grünenthal’s product portfolio, brands, ingredients and indication range.

... Products

Explore our media section and access a range of materials relating to our company, people, medicines and medical devices.

... Media

Grünenthal is a global leader in pain management and related diseases. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on moving towards our vision of a world free of pain. Explore our recent stories to see what drives us.

... Our Stories

In this section you will find both current and archived press releases published from 2013 onwards by Grünenthal GmbH, Germany.

... Press releases

... Statements

Journalists are invited to use our corporate publications for their reporting. The list contains business related publication like the company presentation or the code of conduct. .

... Corporate publications

Journalists are invited to use images from our library to illustrate their reporting. The library contains company and R&D related pictures.

... Image resources

The library contains a set of company footage. Journalists are invited to use the video material to illustrate their reporting.

... Video resources

A World Free of Pain

Out now: Virtual company showcase

Grünenthal is a global leader in pain management.

Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better, and innovation is our passion. We are focusing all our activities and efforts on working towards our vision of a world free of pain.

Katrin Fleischer, Global Regulatory Strategy

Sabine Hess, Technician Cellular & Molecular Biology

Andrew Lockhart, Head Translational and Disease Understanding Unit

Grünenthal Stories

View All

20 countries certified Great Place to Work®

Record-high results and more entities certified in 2024 Great Place to Work® survey

More than 3,700 Grünenthal employees gave feedback during the global Great Place to Work® survey in 2024. 83% of them consider Grünenthal a great place to work. In addition, 20 of our operating countries were certified as a Great Place to Work.

18 October 2024

Karen’s story: Living with osteoarthritis of the knees

Our Grünenthal colleague Karen shares her experience of living with osteoarthritis in her knee.

12 October 2024

Group of smiling warehouse workers at our production site in Chile

Our holistic approach to health

Every day, 4,400 employees worldwide drive Grünenthal forward. They can only make that impact if they are safe and healthy. How is Grünenthal ensuring wellbeing for its global team? We asked Director Global Environment, Health & Safety, Fuad Mahmood.

01 October 2024

Leveraging the latest science

Existing medicines bring pain relief for some patients – but not all of them. Jan Adams, Chief Scientific Officer, explains how researchers at Grünenthal are leveraging the latest science to develop next-generation treatments for pain management.

27 September 2024

Bringing joy into patients’ lives

Pain takes away the joy of living. Medicines can bring it back. Every day, Mariángeles Caro Cabello feels inspired by the positive and poignant impact of her work at Grünenthal. And after 20 years with our company, she has some deeply moving stories to tell…

26 September 2024

All Grünenthal sites now powered by 100% green electricity

100% renewable electricity

Energy contributes more than three-quarters of greenhouse gas emissions worldwide. That is why people and businesses are switching to green energy. And Grünenthal’s manufacturing sites now use 100 percent renewable electricity.

12 September 2024

NOP First-In-Human-Trial Announcement Grünenthal

First participants enrolled in Phase I NOP trial

Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the pharmacokinetic characteristics of the compound after single and multiple ascending doses. The results of the trial are expected in Q3 2025.

Get more insides in our Press Release

Annual Report 2023/24

4,400 Grünenthal employees worldwide join forces every day to drive progress towards our vision of a World Free of Pain. Together, we achieved record revenues in 2023. And our scientists made important progress with developing innovative medicines for pain patients.

Our most recent report shares information about our company’s strategy, highlight projects and financial performance.

Check out the Grünenthal Report.

Responsibility Report 2023

Grünenthal’s strategy and culture are closely tied to its deep commitment to conducting business responsibly. We aim to have a net-positive impact on patients, employees, partners, and wider society. Each year, we publish our progress in a detailed and externally audited report – in line with the Global Reporting Initiative (GRI) standards.

Check out our latest Responsibility Report.

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to resiniferatoxin for pain associated with knee osteoarthritis (OA). The investigational, non-opioid medicine is currently in Phase III clinical development.

Knee OA affects more than 360 million people worldwide. Patients often experience severe pain, and many are impacted in their daily activities. If approved, resiniferatoxin could become a meaningful treatment option providing long-lasting pain relief and functional improvement of the affected joint.

Learn more about our asset and how it may address one of the most common and severe symptoms in knee OA

Download PR FDA Breakthrough Therapy Designation for Grünenthal’s resiniferatoxin

Careers

Working at Grünenthal means experiencing the impact you can have on the results we achieve and the lives of the patients we serve.

Join forces.

Make an impact.

Innovate for a world free of pain.

Visit our careers website